Which Medicines Are Used for FGFR2 Positive Cholangiocarcinoma Sourcing and Regulations
Author: Dr. Sarah Mitchell
On September 15, 2026, international precision oncology panels published a review on targeted therapies for intrahepatic cholangiocarcinoma (iCCA). FGFR2 genetic fusions occur in approximately 10-15% of intrahepatic bile duct cancers, making targeted kinase inhibitors the primary line of treatment.
At Onco Medicine, we specialize in sourcing and delivering verified FGFR2-directed therapies directly to clinics and patients globally under strict compliance protocols.
Approved FGFR2-Targeted Therapies
Oncologists rely on the following targeted inhibitors to treat FGFR2-positive cholangiocarcinoma:
- Infigratinib (Lucinfig): Formulated as oral capsules, this selective kinase inhibitor is taken once daily for 21 days on, followed by 7 days off, in a 28-day cycle.
- Pemigatinib: An oral small-molecule inhibitor of FGFR1, 2, and 3, taken daily on a similar 21/7 schedule.
- Futibatinib: A covalent inhibitor that forms an irreversible bond with FGFR receptors, taken continuously.
Contact our support team at support@onco-medicine.com or chat via WhatsApp +91 94275 19809.
